Telehealth Content Marketing: What GLP-1 Brands Can Publish

Telehealth content marketing for a GLP-1 brand means publishing pages that bring in customers: the brand’s own educational and landing pages, plus affiliate, influencer and comparison content that other people publish for it. FDA claim lines and FTC substantiation and disclosure rules limit all of it. The table below shows which rule attaches to each format.

Telehealth content marketing for GLP-1 brands: the formats and the rule each one carries

A GLP-1 brand has 8 content formats to choose from, and each one carries a different rule and a different party who is exposed. The table maps them. Rules checked as of November 2, 2026.

The pattern is that the claim travels. A sentence approved on a landing page shows up in an affiliate review, an influencer caption and a refill email, so one claims list has to govern all four.

What own-site content does for a GLP-1 brand, and where YMYL applies

Own-site content captures search demand at the stage when a buyer is comparing providers, and it feeds every other channel with approved wording. Telehealth SEO for a GLP-1 brand comes down to topic clusters around the questions buyers ask, internal links between those pages, and matching each page to a business intent rather than to raw traffic.

Google treats health topics with extra care. The Search Quality Rater Guidelines of September 11, 2025 say that for clear YMYL (“Your Money or Your Life”) topics, “we have very high Page Quality rating standards.” The guidelines are what Google’s raters use to evaluate search quality, not a ranking checklist. Our business reading is that a page explaining a treatment sits closer to that line than a page describing your service, so it deserves more review and a named owner.

The balance between paid and organic channels is covered in GLP-1 marketing strategy, so this page doesn’t repeat it.

Claims on your own pages: the FDA and FTC lines

FDA is enforcing against claims made on telehealth websites, and the FTC applies a separate substantiation standard to the same pages.

On March 3, 2026, FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products on their websites. FDA called it the second group of warning letters to telehealth firms since it launched a crackdown on misleading direct-to-consumer drug advertising in September 2025. The primary violations were claims implying sameness with FDA-approved products, and branding a product with the telehealth firm’s own name or trademark in a way that implies it is the compounder.

FDA’s reminder page for telehealth companies, current as of June 15, 2026, repeats those points. It also warns against calling a compounded drug the same as an approved drug, and against claiming it is sourced from an FDA-approved or FDA-licensed facility, because FDA does not approve or license any facility. The full claims list lives in misleading ad claims and the FDA, and compounded GLP-1 explained covers the background.

The FTC adds 3 rules that matter for content:

• Advertising must be truthful, and advertisers must have adequate substantiation for every objective claim before they publish. For health claims, the general standard is competent and reliable scientific evidence.
• An ad is judged by its net impression. The FTC’s own example is a weight-loss product website whose medical images and terminology conveyed a false claim of scientific proof.
• Testimonials don’t substantiate a claim. An advertiser can’t make a claim through a testimonial that it couldn’t make directly, and “Individual results may vary” won’t change how readers interpret a results claim.

The FTC defines advertising broadly. It includes “social media and influencer marketing” and other digital content, and all of it must meet the same truth-in-advertising principles.

Affiliate and influencer content: who is responsible and what the disclosure must look like

When an affiliate or influencer publishes about a GLP-1 program, the brand stays responsible for what is said, and the publisher has to disclose the financial connection clearly. The FTC’s guidance says an advertiser needs a reasonable program to train and monitor its network. The program should:

1. Explain what members can and can’t say about the product.
2. Instruct them on exactly how to disclose their connection.
3. Periodically search for what they are saying.
4. Take action on questionable practices.

The FTC adds that a network devoted to health products may need more supervision than one promoting a fashion line, and that regular monitoring too burdensome to run is a reason to pre-approve posts instead. In its health-products guidance, the FTC gives the example of a marketer that pays a blogger who then claims the product cures a condition the marketer can’t substantiate. The marketer is liable for the blogger’s claim, and the post needs a clear disclosure of the payment.

On wording, the FTC says an affiliate should disclose the relationship clearly on the site, close to the recommendation. “Affiliate link” alone may not tell readers that the publisher gets paid, and a “buy now” button isn’t adequate. FTC staff say “Commissionable link” is probably not a clear disclosure, while “paid link” next to the link should be adequate. For social posts, the FTC says a disclosure in the comments is easily avoidable, and it names the start of a post as a place readers will see it. A brand running a contest should tell participants where to place the disclosure.

The detailed rules for creator posts are in GLP-1 influencer rules, and the checking routine is in monitoring affiliate ads for GLP-1 offers.

Comparison and review sites run by a brand, a network or us: the Section 465.6 line

A comparison or review site that a business controls can’t claim to be independent. Section 465.6 of the FTC’s Consumer Reviews and Testimonials Rule, effective October 21, 2024, prohibits a business from materially misrepresenting that a website, organization or entity it controls provides independent reviews or opinions about a category of products that includes its own. The rule allows courts to impose civil penalties for knowing violations.

The FTC’s staff Q&A adds 3 details that matter here:

• The provision reaches beyond websites. It covers any “website, organization, or entity,” and the FTC’s example is a company that created a fake seal program and awarded the seal to its own products.
• An express claim of independence can’t be cured by a contradicting disclosure of ownership. If a site only implies independence, a disclosure may or may not fix it, depending on the net impression of the page.
• A site that reviews and ranks your own products and competitors’ products is the exact situation the FTC discusses.

The FTC’s health-products guidance reaches the same point from another angle. Its example is an advertiser that created and owns an apparently independent website without disclosing the ownership. The FTC says that advertiser is responsible for the accuracy of the claims on the site and must disclose that it owns it.

For GLP-1 telehealth, the practical reading is plain. If a brand, an affiliate network or an agency operates a comparison site, the site should say who runs it, near the top, and shouldn’t use words such as independent, unbiased or tested unless that is true. The same standard applies to comparison sites we operate.

How we run it

We treat content as one system with one set of approved claims, and we run it across several channels at once. The GLP1.partners media team buys traffic on Meta, Outbrain and TikTok, runs its own comparison sites, manages an affiliate network, and works with Instagram influencers. Because the same message passes through all of those, the claims come from the brand, and affiliates use brand-approved claims.

On retention, the GLP1.partners media team’s experience is that the affiliates whose customers keep refilling are the ones who give customers all the information they need and make them want to stay with the brand. Content that sets honest expectations before the first order protects the refills that come after it.

How a brand’s content review works with our network is settled on a call, not on this page.

A seven-step plan to set up GLP-1 content without owning every claim yourself

A brand can run this plan without us, and it works whether most content comes from your own team or from affiliates.

1. Inventory every claim in use. Collect the claims on your site, ads, affiliate pages, influencer posts and emails, and put them in one sheet with the page where each appears.
2. Name an owner for claim approval. One person or role approves each claim. Link each approved claim to the source or substantiation that supports it.
3. Set the format map. Use the table above to decide which formats you publish, which you leave to partners, and which you don’t use at all.
4. Write disclosure placement into partner terms. Give affiliates and influencers the exact disclosure wording and where it goes, for example at the start of a post.
5. Build a pre-publish check. Ask 4 questions of each page. Does every claim match the approved list? Does the net impression match the claims? Is the connection disclosed? Does any site we control claim independence?
6. Set a review cadence. FDA has issued warning letters in groups, so review your claims list on a schedule and again whenever FDA updates its telehealth page.
7. Measure qualified progression, not sessions. Track how many visitors move from content to a completed intake and to a second order, because pageviews don’t show whether a page is bringing in the right visitors.

Sources and dates

Sources accessed November 2, 2026.

• FDA, “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s,” March 3, 2026.
• FDA, “FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs,” content current as of June 15, 2026.
• FTC, “Health Products Compliance Guidance,” December 2022.
• FTC, “FTC’s Endorsement Guides: What People Are Asking,” June 2023.
• FTC, “The Consumer Reviews and Testimonials Rule: Questions and Answers,” November 2024.
• Google, Search Quality Rater General Guidelines, September 11, 2025.

FAQ

Who is liable for an affiliate’s claims about a GLP-1 program?

The brand is responsible for what others say on its behalf. The FTC says a company is “ultimately responsible for what others do on your behalf” and that delegating promotion doesn’t remove that responsibility. Affiliates and networks can carry their own exposure too.

Does “individual results may vary” fix a results testimonial?

No. The FTC says that statements like that won’t change how readers interpret a claim of specific results. The advertiser needs proof that the result is typical, or has to disclose the generally expected result clearly and conspicuously.

Can a brand publish its own comparison page?

Yes, with conditions. The page can’t claim to be independent, and a disclosure of ownership won’t cure an express independence claim. The page must also be accurate and substantiated like any other advertising.

Is a disclosure in the comments or a footer enough for affiliate and influencer posts?

Usually not. The FTC says a disclosure in the comments to a post is easily avoidable, and that the disclosure should sit close to the endorsement it relates to. Give partners the exact wording and location in writing.